Progyny Reports Third-Quarter 2026 Revenue of $341.25M, EPS of $0.32
Progyny said third-quarter revenue and net income increased year over year, citing higher client and covered-life counts. Gross margin improved, while operating expenses declined.
Progyny’s third-quarter revenue and net income increased year over year as higher client and covered-life counts lifted fertility benefits and Progyny Rx revenue. Gross margin improved on care-management efficiencies and lower stock-based compensation, while operating expenses declined, primarily d…